Vivimed Labs Limited · NSE:VIVIMEDLAB
Vivimed Labs — FY2016 Earnings Presentation
15 slides from Vivimed Labs's earnings presentation, May 30, 2016
Slide 1: Q4 and Full Year FY2016 Earnings Presentation
Q4 and Full Year FY2016 Earnings Presentation May 30, 2016 Transitioning into the Next Phase of Growth
Slide 2: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed Labs’ future business developments and economic performance. Whil
Slide 3: Transitioning into the Next Phase of Growth
Transitioning into the Next Phase of Growth Preferred vendor to regulated markets due to a track record of regulatory compliance Leveraging chemistry skills and manufacturing platform to scale up CMO & Generic opportunities New opportunities of forward integration with the API business; US FDA compl
Slide 4: Performance Highlights
Performance Highlights FY2016 vs. FY2015 Net Sales EBITDA Net Profit Rs. 13,564 mn Rs. 2,429 mn Rs. 837 mn (2.1)% +9.0% +16.1% 27.6% EBITDA Net Profit Margin: Margin: 72.4% 17.9% 6.2% +183 bps +97 bps Healthcare Specialty Chemicals 4 │ Earnings Presentation
Slide 5: Management Perspectives
Management Perspectives Commenting on the performance, Mr. Santosh Varalwar, Managing Director of Vivimed Labs said: “The performance for the year has been encouraging and we continue to invest to prepare ourselves for the next phase of growth. Though our top-line for FY2016 was marginally lower, we
Slide 6: Financial Performance
Financial Performance Consolidated financial summary Q4 y-o-y Q3 q-o-q Full Year y-o-y (Rs. million) FY2016 FY2015 Growth (%) FY2016 Growth (%) FY2016 FY2015 Growth (%) Net Sales 3,500 3,567 (1.9)% 3,319 5.5% 13,564 13,860 (2.1)% EBITDA 512 526 (2.6)% 613 (16.4)% 2,429 2,228 9.0% Margin (%) 14.6% 14
Slide 7: Performance Discussion
Performance Discussion FY2016 vs. FY2015 Revenues decreased by 2.1% to Rs. 13,564 million primarily due to the change in product mix in the Specialty Chemicals business and eventual divestiture of certain identified product segments o Healthcare segment recorded a moderate growth of 4.3% to reach
Slide 8: Financial Performance
Financial Performance Net Sales EBITDA and Margins 3,567 3,500 3,330 3,415 3,319 20.2% 18.5% 18.5% Rs. Million Rs. Million 14.8% 14.6% 526 672 632 613 512 Q4 FY15 Q1 FY16 Q2 FY16 Q3 FY16 Q4 FY16 Q4 FY15 Q1 FY16 Q2 FY16 Q3 FY16 Q4 FY16 EBITDA Margin (%) Net Profit and Margins 7.3% 7.0% 6.9% Rs. Milli
Slide 9: Key Ratios
Key Ratios FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 Net Worth (Rs. million) 1,967 4,748 5,091 5,604 5,592 5,852 Net Debt (Rs. million) 2,959 5,279 6,414 8,591 9,852 8,618 Including current maturities of LT Debt Fixed Assets (Rs. million) 2,643 5,953 7,090 8,079 8,135 8,142 ROE (%) 24.8% 18.4% 18.8%
Slide 10: Recent Corporate Developments
Recent Corporate Developments Update on the Clariant Transaction In January 2016, the Company successfully closed the first stage of the transaction; received proceeds of Rs. 2,580 million Second stage of the business transfer is progressing as per schedule and is expected to be complete by Q1 F
Slide 11: Consolidated Quarterly P&L Statement
Consolidated Quarterly P&L Statement Profit & Loss Statement (Rs. million) Q4 FY15 Q1 FY16 Q2 FY16 Q3 FY16 Q4 FY16 Revenues Net Sales / Income from Operations (Net of Excise Duty) 3,562 3,315 3,370 3,299 3,472 Other Operating Income 5 14 45 20 29 Total Revenues 3,567 3,330 3,415 3,319 3,500 Total ex
Slide 12: Consolidated Segment Performance
Consolidated Segment Performance Q4 y-o-y Q3 q-o-q Full Year y-o-y (Rs. million) FY2016 FY2015 Growth (%) FY2016 Growth (%) FY2016 FY2015 Growth (%) Segment Revenue 3,472 3,562 (2.5)% 3,299 5.2% 13,456 13,801 (2.5)% Specialty chemicals 945 1,497 (36.9)% 869 8.8% 3,714 4,462 (16.8)% Healthcare 2,527
Slide 13: Consolidated Balance Sheet
Consolidated Balance Sheet Liabilities (Rs. million) Mar-15 Sep-15 Mar-16 Assets (Rs. million) Mar-15 Sep-15 Mar-16 Shareholders funds Non current assets Share capital Tangible assets 6,963 6,925 7,149 Equity share capital 162 162 162 Intangible assets 1,172 1,013 993 Prefrence share capital 639 639
Slide 14: Glossary
Glossary ANDA: Abbreviated New Drug Application API: Active Pharmaceutical Ingredients CEP: Certificates of Suitability to the monographs of European Pharmacopoeia CMO: Contract Manufacturing Organization DMF: Drug Master File FDF: Finished Dosage Formulation GMP: Good Manufacturing Pr
Slide 15: Vivimed Labs Limited
Vivimed Labs Limited (CIN: L02411KA1988PLC009465) Veernag Towers, Habsiguda, Hyderabad 500 007 www.vivimedlabs.com Phone: +91 40 2717 6005 / 06 Fax: +91 40 2715 0599 Raja Prasad. B +91 40 2717 6005 Vivimed Labs Limited Rajaprasad.B@vivimedlabs.com Saket Somani / Bijay Sharma +91 22 6169 5988 Churchg